Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

TCT 2021 | Outcomes of allogeneic stem cell transplantation in elderly patients

Yngvar Fløisand • 11 Feb 2021
TCT 2021
Acute Myeloid Leukemia Leukemia Myelodysplastic Syndromes

Yngvar Floisand, MD, PhD, Oslo University Hospital, Oslo, Norway, discusses outcomes associated with allogeneic stem cell transplantation in elderly patients (65 years or above) with acute myeloid leukemia or myelodysplastic syndrome, the findings of which support the use of this treatment approach in elderly patients. This interview took place during the Transplantation & Cellular Therapy (TCT) 2021 Meetings.

More from Yngvar Fløisand

4:24
Long-term follow-up of a "fast-DC" immunotherapy as a post-remission strategy for AML
Yngvar Fløisand • 11 Feb 2021

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals